Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.54 |
| ▸ | CKS1B | P61024 | 2/20 | 0.53 |
| ▸ | SKP1 | P63208 | 2/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.53 |
| ▸ | PGK1 | P00558 | 1/20 | 0.52 |
| ▸ | ADK | P55263 | 1/20 | 0.51 |
| ▸ | WNT3A | P56704 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320120 | 0.84 | GPR119 (0.56) | CKS1BSKP1SKP2GPR119MAP4K4 | |
| SCHEMBL6787575 | 0.83 | ADK (0.63) | RETCKS1BSKP1SKP2PGK1 | |
| SCHEMBL16283584 | 0.81 | ADK (0.56) | RETCKS1BSKP1SKP2PGK1 | |
| SCHEMBL30791110 | 0.81 | ADORA2A (0.53) | CKS1BSKP1SKP2GPR119 | |
| SCHEMBL20516341 | 0.81 | ADORA2A (0.53) | CKS1BSKP1SKP2GPR119 | |
| SCHEMBL6788585 | 0.81 | RET (0.55) | RETCKS1BSKP1SKP2ADK | |
| SCHEMBL1904170 | 0.81 | ADK (0.59) | RETCKS1BSKP1SKP2PGK1 | |
| SCHEMBL30893596 | 0.81 | ADK (0.59) | RETCKS1BSKP1SKP2PGK1 | |
| SCHEMBL3753329 | 0.81 | CKS1B (0.45) | CKS1BSKP1SKP2WNT3AGPR119 | |
| SCHEMBL6955414 | 0.80 | ZAP70 (0.55) | RETCKS1BSKP1SKP2PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552029-B1 | For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis | CELLTECH R&D LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
| EP-0934304-B1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-6114333-A | 2-Pyrimidineamine derivatives and processes for their preparation | CELLTECH THERAPEUTICS LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| US-6093716-A | Substituted 2-pyrimidineamines and processes for their preparation | CELLTECH THERAPEUTICS, LIMITED (GB) | 2000-07-25 | — | — | US | disclosed |
| EP-0934304-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998018782-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-05-07 | — | — | WO | disclosed |